

Submitted For: IN0972K1B  
Serial No.: 10/028,251  
Filed: December 20, 2001



PATENT  
CASE IN0972K1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X  
In re Application of: :  
  
GUZI ET AL : Examiner: E. Huang  
  
For Patent For: FARNESYL PROTEIN : Group Art Unit: 1625  
TRANSFERASE INHIBITORS : Date: July 5, 2001  
:  
:  
  
Serial No.: 09/465,523 :  
  
Filed: December 16, 1999 :  
-----X

Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Information about other applications is provided below.

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST  
CLASS MAIL IN AN ENVELOPE ADDRESSED TO ASSISTANT  
COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 ON


July 5, 2001  
(DATE OF DEPOSIT)

HENRY C. JEANETTE REG. NO. 30,856  
(REGISTERED REPRESENTATIVE)

Henry C. Jeanette July 5, 2001  
(SIGNATURE AND DATE)


Applicants are submitting a 1449 form citing EP0157399 published October 9, 1985.

Applicants also wish to inform the Examiner of Copending Application Serial No. 09/469,465 filed December 22, 1999 (our Docket No. IN0887K1), claiming priority to Provisional Application No. 60/113,405 filed December 23, 1998, which discloses compounds of the formula:




or a pharmaceutically acceptable salt or solvate thereof, wherein

Q is:



Z represents hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl,



heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, or -CY<sup>3</sup>Y<sup>4</sup> wherein Y<sup>3</sup> and Y<sup>4</sup> independently represent alkyl and aryl or Y<sup>3</sup> and Y<sup>4</sup>, together with the attached carbon atom (-C), can form a cycloalkyl or a cycloalkenyl ring;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>20</sup>, R<sup>22</sup>, R<sup>30</sup> and R<sup>32</sup> independently represent hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R<sup>25</sup> can represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl or -OR<sup>40</sup> wherein R<sup>40</sup> can represent alkyl, aryl, arylalkyl,

cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

Y represents aryl, heteroaryl, heterocycloalkyl or cycloalkyl,


t is zero, 1, 2 or 3;

w is zero or 1; and


A is nothing, hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyano, heteroaryl or heteroarylalkyl.

Y can be an imidazole group.


Example 28S on page 44 discloses the compound:




Example 28T on page 44 discloses the compound:




Example 28Y on page 47 discloses the compounds:



Example 237 on page 71 discloses the compound:



Respectfully submitted,

  
Henry C. Jeanette  
Reg. No. 30,856  
Attorney for Applicants  
(908) 298-5041



PATENT CASE: IN0972K1B

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X	:	
In re Application of: <b>GUZI et al.</b>	:	Examiner: Evelyn Mei Huang
	:	
For Patent: <b>Farnesyl Protein Transferase</b>	:	Date: January 14, 2003
<b>Inhibitors</b>	:	
	:	Group Art Unit: 1625
Serial No.: 10/028,251	:	
	:	
Filed: December 20, 2001	:	
-----X	:	

Schering-Plough Corporation  
Kenilworth, New Jersey 07033

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Enclosed is a PTO-1449 Form (one page) listing patents known to Applicants which may be relevant to this application. This Statement is being filed prior to the first substantive Office Action from the Examiner and, therefore, no fee should be due.

Copies of these publications were previously submitted in Applicants' Parent Application Serial No. 09/465,523 filed December 16, 1999 from which this application claims the benefit of. Therefore, copies of these documents are not being submitted herewith. The Examiner is requested to notify the undersigned if copies of the documents are desired.

Documents AB, AC and AQ were cited on a PTO-892 form in Applicant's Parent Application.

Enclosed is a copy of Applicants' PTO-1449 form from an Amendment as well as Applicants' Information Disclosure Statements from Applicants' parent Application.

In re Application of: **Guzi et al.**  
Serial No.: 10/028,251  
Filed: December 20, 2001

As per 37 CFR 1.97, because the IDS is being filed prior to the mailing of a first office action on the merits, applicants respectfully request consideration of the IDS by the Examiner.

Applicants respectfully request that the cited documents be made of record in the above- identified Application.

Respectfully submitted,

Robert L. Bernstein  
Robert L. Bernstein  
Reg. No. 46,020  
Attorney for Applicants  
(908) 298-3985

RLB:sh

**I HEREBY CERTIFY THAT THIS  
CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE  
AS FIRST CLASS MAIL IN AN ENVELOPE  
ADDRESSED TO ASSISTANT COMMISSIONER  
FOR PATENTS, WASHINGTON, D.C. 20231  
ON January 14, 2003**

ROBERT L. BERNSTEIN  
(REGISTERED REPRESENTATIVE)

Robert L. Bernstein 1/14/03  
(SIGNATURE AND DATE)

Submitted For: N0972K1B  
Serial No.: 107028,251  
Filed: December 20, 2001

PATENT  
CASE IN0972K1



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X  
In re Application of: :  
  
GUZI ET AL : Examiner: E. Huang  
  
For Patent For: FARNESYL PROTEIN : Group Art Unit: 1625  
TRANSFERASE INHIBITORS : Date: July 19, 2001  
  
: :  
Serial No.: 09/465,523 :  
  
Filed: December 16, 1999 :  
-----X

Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530

Commissioner for Patents  
Washington, D.C. 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:


Submitted herewith is Applicants' 1449 form and a copy of the reference cited therein. Applicants request that these documents be made of record in the above-identified application.

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 ON

July 19, 2001  
(DATE OF DEPOSIT)

HENRY C. JEANETTE REG. NO. 30,856  
(REGISTERED REPRESENTATIVE)  
Henry C. Jeanette July 19, 2001  
(SIGNATURE AND DATE)

Respectfully submitted,

  
Henry C. Jeanette  
Reg. No. 30, 856  
Attorney for Applicants  
(908) 298-5041